ATE223424T1 - Quinazolinon-verbindungen - Google Patents

Quinazolinon-verbindungen

Info

Publication number
ATE223424T1
ATE223424T1 AT98902115T AT98902115T ATE223424T1 AT E223424 T1 ATE223424 T1 AT E223424T1 AT 98902115 T AT98902115 T AT 98902115T AT 98902115 T AT98902115 T AT 98902115T AT E223424 T1 ATE223424 T1 AT E223424T1
Authority
AT
Austria
Prior art keywords
phosphate
alkyl
optionally substituted
compounds
derivative
Prior art date
Application number
AT98902115T
Other languages
English (en)
Inventor
Roger John Griffin
Alan Hilary Calvert
Nicola Jane Curtin
David Richard Newell
Bernard Thomas Golding
Original Assignee
Univ Newcastle Ventures Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Newcastle Ventures Ltd filed Critical Univ Newcastle Ventures Ltd
Application granted granted Critical
Publication of ATE223424T1 publication Critical patent/ATE223424T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/6512Six-membered rings having the nitrogen atoms in positions 1 and 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/91Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/6512Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT98902115T 1997-02-01 1998-01-30 Quinazolinon-verbindungen ATE223424T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9702701.5A GB9702701D0 (en) 1997-02-01 1997-02-01 Quinazolinone compounds
PCT/GB1998/000303 WO1998033802A1 (en) 1997-02-01 1998-01-30 Quinazolinone compounds

Publications (1)

Publication Number Publication Date
ATE223424T1 true ATE223424T1 (de) 2002-09-15

Family

ID=10807378

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98902115T ATE223424T1 (de) 1997-02-01 1998-01-30 Quinazolinon-verbindungen

Country Status (10)

Country Link
US (1) US6156739A (de)
EP (1) EP0966476B1 (de)
JP (1) JP2001511776A (de)
KR (1) KR20000070467A (de)
AT (1) ATE223424T1 (de)
AU (1) AU5873998A (de)
CA (1) CA2278290C (de)
DE (1) DE69807661D1 (de)
GB (1) GB9702701D0 (de)
WO (1) WO1998033802A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200101498T2 (tr) * 1998-11-27 2001-11-21 Basf Aktiengesellschaft İkameli benzimidazoller ve parp inhibitörleri olarak kullanımları
DE19916460B4 (de) * 1999-04-12 2006-12-21 Abbott Gmbh & Co. Kg Substituierte Benzimidazole, deren Herstellung und Anwendung
PL210415B1 (pl) 1999-01-11 2012-01-31 Agouron Pharma Pochodne indolu, środek farmaceutyczny i zastosowanie pochodnych indolu
WO2000042025A1 (en) * 1999-01-14 2000-07-20 Meiji Seika Kaisha, Ltd. Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives
DE19918211A1 (de) * 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
MXPA02009216A (es) * 2000-03-20 2003-12-11 N Gene Res Lab Inc Derivados de amidoxima de acido propencarboxilico, un proceso para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
EP1288216A1 (de) * 2000-04-18 2003-03-05 Sumitomo Pharmaceuticals Company, Limited Tricyclische chinazolindione
SI2223922T1 (sl) * 2000-04-25 2016-04-29 Icos Corporation Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US7514067B2 (en) * 2000-04-25 2009-04-07 President And Fellows Of Harvard College Methods for tumor diagnosis and therapy
DE10034801A1 (de) * 2000-07-18 2002-01-31 Bayer Ag Substituierte Amidoalkyl-uracile und ihre Verwendung
WO2002044157A2 (en) * 2000-12-01 2002-06-06 Iconix Pharmaceuticals, Inc. Parb inhibitors
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
KR20030071029A (ko) * 2002-02-27 2003-09-03 주식회사 팜제니아 항암제 및 방사선 치료 증진제로서 유용한 조성물
DK1558585T3 (da) 2002-10-04 2014-01-06 Prana Biotechnology Ltd Neurologisk aktive forbindelser
EP1582520A1 (de) * 2002-11-12 2005-10-05 Mochida Pharmaceutical Co., Ltd. Neue parp-inhibitoren
EP1608317B1 (de) 2003-03-25 2012-09-26 Takeda Pharmaceutical Company Limited Dipeptidylpeptidase-hemmer
EP1625122A1 (de) 2003-05-14 2006-02-15 Takeda San Diego, Inc. Dipeptidylpeptidase-hemmer
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790736B2 (en) 2003-08-13 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EA013427B1 (ru) 2004-03-15 2010-04-30 Такеда Фармасьютикал Компани Лимитед Ингибиторы дипептидилпептидазы
ES2605792T3 (es) 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006078711A2 (en) 2005-01-19 2006-07-27 Mgi Gp, Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp
CN101242822B (zh) 2005-07-18 2011-08-24 彼帕科学公司 治疗卵巢癌的药物
JP5027137B2 (ja) 2005-09-14 2012-09-19 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤の投与
KR101368988B1 (ko) 2005-09-16 2014-02-28 다케다 야쿠힌 고교 가부시키가이샤 디펩티딜 펩티다제 억제제
CA2629376C (en) 2005-11-14 2015-06-09 Centre National De La Recherche Scientifique - Cnrs Inhibitors of parp activity and uses thereof
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
NZ590271A (en) 2006-04-14 2011-12-22 Prana Biotechnology Ltd 9-hydroxy-3-substituted-4H-pyrido[1,2-a]pyrimidin-4-ones and 9-hydroxy-3-substituted-4H-pyrido[1,2-a]pyrimidin-4-thiones
US20070259937A1 (en) 2006-05-02 2007-11-08 Giranda Vincent L Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US7994222B2 (en) 2006-09-05 2011-08-09 Bipar Sciences, Inc. Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds
WO2008030883A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
CN101616673A (zh) * 2006-09-13 2009-12-30 武田药品工业株式会社 2-[6-(3-氨基-哌啶-1-基)-3-甲基-2,4-二氧代-3,4-二氢-2h-嘧啶-1-基甲基]-4-氟-苄腈的用途
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8236802B2 (en) 2007-10-03 2012-08-07 Eisai Inc. PARP inhibitor compounds, compositions and methods of use
AU2008321128A1 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
CN101531638B (zh) * 2008-03-13 2011-12-28 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
CN101628913B (zh) 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CN102271683B (zh) 2008-11-13 2014-07-09 吉里德卡利斯托加公司 恶性血液病的治疗
SG174529A1 (en) 2009-03-24 2011-10-28 Gilead Calistoga Llc Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
MX2012000817A (es) 2009-07-21 2012-05-08 Gilead Calistoga Llc Tratamiento para desordenes del higado con inhibidores pi3k.
EP2611300B1 (de) * 2010-09-03 2016-04-06 Bayer Intellectual Property GmbH Substituierte anellierte dihydropyrimidinonderivate
ES2590682T3 (es) 2010-12-02 2016-11-23 Shanghai De Novo Pharmatech Co Ltd. Derivados heterocíclicos, procesos de preparación y usos médicos de los mismos
WO2012111017A1 (en) * 2011-02-15 2012-08-23 Concil Of Scientific & Industrial Research 3-arylethynyl substituted quinazolinone compounds
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
EP2788003A4 (de) * 2011-12-09 2015-05-27 Demerx Inc Phosphatester von noribogain
CA2864305C (en) 2012-03-05 2021-02-16 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
EP2900643B1 (de) * 2012-09-26 2017-09-27 Merck Patent GmbH Quinazolinone derivate als parp inhibitoren
WO2014087165A1 (en) * 2012-12-06 2014-06-12 University Of Bath Tankyrase inhibitors
CA2896133A1 (en) 2012-12-20 2014-06-26 Demerx, Inc. Substituted noribogaine
ES2752552T3 (es) 2013-12-20 2020-04-06 Gilead Calistoga Llc Métodos de proceso para inhibidores de fosfatidilinositol 3-quinasa
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー (s)−2−(1−(9h−プリン−6−イルアミノ)プロピル)−5−フルオロ−3−フェニルキナゾリン−4(3h)−オンの塩酸塩の多形形態
NZ726360A (en) 2014-06-13 2018-04-27 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
US10874641B2 (en) 2016-07-28 2020-12-29 Mitobridge, Inc. Methods of treating acute kidney injury
MA46779A (fr) 2016-11-02 2019-09-11 Health Research Inc Traitement combiné avec des conjugués anticorps-médicament et des inhibiteurs de parp
CN117229224A (zh) * 2022-06-07 2023-12-15 中国药科大学 喹唑啉-4(3h)-酮类化合物、制法、组合物和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024410A1 (en) * 1994-03-08 1995-09-14 Otsuka Pharmaceutical Factory, Inc. Phosphonic diester derivative
GB9404485D0 (en) * 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues

Also Published As

Publication number Publication date
CA2278290C (en) 2005-05-10
JP2001511776A (ja) 2001-08-14
CA2278290A1 (en) 1998-08-06
EP0966476A1 (de) 1999-12-29
WO1998033802A1 (en) 1998-08-06
KR20000070467A (ko) 2000-11-25
EP0966476B1 (de) 2002-09-04
AU5873998A (en) 1998-08-25
GB9702701D0 (en) 1997-04-02
US6156739A (en) 2000-12-05
DE69807661D1 (de) 2002-10-10

Similar Documents

Publication Publication Date Title
DE69807661D1 (de) Quinazolinon-Verbindungen
GB9404485D0 (en) Benzamide analogues
MX9800577A (es) Derivados de 4,5-diaril oxazol.
ES2147836T3 (es) Derivados de 4,5-diariloxazol.
AU689304B2 (en) Quinazoline derivative
GEP20033001B (en) Alkynyl-Substituted Quinolin-2-One Derivatives Useful As Anticancer Agents
ES2149186T3 (es) Derivados de dihidrochalcona hipoglicemicos.
AUPR177300A0 (en) Therapeutic methods
GEP20032953B (en) Antitumor Agents
DE69506197D1 (de) Verwendung eines Ascorbyl-tocopherylphosphats zur Herstellung eines Arzneimittels zur Behandlung der Pankreatitis
DE69312567D1 (de) 2-Formylpyridin-Thiosemicarbazonderivate, ihre Herstellung und ihre Verwendung als Antitumor Mittel
BR9506552A (pt) Método de inibição de integrase retroviral
WO1990014831A3 (en) 3'-azido-2',3'-dideoxy-5-methylcytidine anti-viral composition
DE69931378D1 (de) Chinazolin derivate und therapeutische verwendungen davon
FR2700166B1 (fr) Dérivés de pyrrolidine, leur préparation et les médicaments les contenant.
CA2228524A1 (en) Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating human malignancies
GB9504497D0 (en) Pharmaceuticals
ATE240329T1 (de) Zytotoxische pyrido(2,3,4-kl)acridinderivate, ihre herstellung und therapeutische verwendung
ATE228359T1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
GB9323403D0 (en) Pharmaceuticals

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties